BioCentury | Nov 6, 2020
Deals

With $1.4B Emisphere buy, Novo gets delivery tech used in Rybelsus

...used in a product crucial to its future, while also buying out that drug’s royalty stream.Novo Nordisk A/S (CSE:NOVO...
...Stephen Hansen contributed to this report.TARGETSGLP-1R (GLP1R) - Glucagon-like peptide-1 receptor Paul Bonanos Rybelsus, oral semaglutide (NN9924, OG217SC) Novo Nordisk A/S Emisphere...
BioCentury | Sep 25, 2020
Product Development

Novo makes obesity pick as amylin/GLP-1 combo promises gastric bypass-like efficacy

...amylin/GLP-1 combo By stephen hansen, associate editor Novo Nordisk...
...for the even-greater efficacy the combo could produce. Novo Nordisk A/S...
...that mimics gastric bypass surgery.” Mads Thomsen, Novo Nordisk...
BioCentury | Sep 18, 2020
Finance

Lava’s $83M series C exemplifies evolution of Novo Ventures’ investing

...to allocate more capital to venture investments.Novo Holdings is the umbrella investment organization for the Novo Nordisk...
...focused on private and public venture investments. Novo Holdings is also the controlling shareholder of Novo Nordisk A/S...
BioCentury | Sep 2, 2020
Regulation

Sept. 1 Quick Takes: House committee to subpoena AbbVie on pricing; plus Athenex, Harmony, AZ, BMS, Novo, and cancer trial guidance

...candidate is under EMA review. Novo’s growth hormone deficiency drug gains FDA approvalFDA approved Sogroya somapacitan from Novo Nordisk A/S...
...Programmed cell death 1 ligand 1 Virginia Li AbbVie Inc. AstraZeneca plc the National Academy of Science FDA Bristol Myers Squibb Co. Novo Nordisk...
BioCentury | Aug 25, 2020
Finance

Seeing path for cholesterol-lowering program, Forbion launches start-up to house former Dezima molecule

...team includes two C-level executives with a history of entering deals around cardiovascular programs with Novo Nordisk A/S (CSE:NOVO...
BioCentury | Aug 21, 2020
Deals

Aug. 20 Quick Takes: Funding for Alzheon’s Alzheimer’s Phase III; plus Merck, FDA guidance, LumiraDx, RACE for Children, blood plasma and Novo-Evotec

...a request for comment from BioCentury.Evotec, Novo pair up to tackle kidney diseaseEvotec SE (Xetra:EVT) and Novo Nordisk A/S...
...E epsilon 4 Paul Bonanos ALZ-801, blu8499, NRM8499, NRM-8499 Keytruda, pembrolizumab (MK-3475, lambrolizumab) Alzheon Inc. Merck & Co. Inc. LumiraDx Ltd. NIH Evotec SE Novo Nordisk A/S covid-19 cov19dx cov19count cov19count...
BioCentury | Jul 28, 2020
Emerging Company Profile

Frazier, Marcadia founders reunite for rare endocrine diseases in MBX’s $34.6M A round

...$289.6 million) in cash and up to CHF86 million in milestones (see “Metabolic Wellspring” ). Novo Nordisk A/S...
BioCentury | Jul 10, 2020
Finance

How buysiders are sizing up commercial launches during the pandemic

...hit harder. She noted that the launch of the oral GLP-1 inhibitor Rybelsus semaglutide from Novo Nordisk A/S...
BioCentury | Jul 10, 2020
Finance

With an eye on ‘underserved’ Nordic biotechs, Eir raises €76M toward first fund

...fund, which Eir hopes will top out at about €100 million. Established biopharmas such as Novo Nordisk A/S...
...and endocrine disorders, stem cells, oncology and fibrosis. He added that diabetes, a key area Novo Nordisk...
BioCentury | Jul 10, 2020
Politics, Policy & Law

Pharmas to invest $1 billion in biotechs to fight AMR as bridge to market reforms

...billion dollar fund The ARM Fund has collected $1 billion from 23 pharmas and the Novo Nordisk...
...products will generate revenues. In a BioCentury Guest Commentary, Lars Rieben Sorenson, chairman of the Novo Nordisk...
Items per page:
1 - 10 of 1737
BioCentury | Nov 6, 2020
Deals

With $1.4B Emisphere buy, Novo gets delivery tech used in Rybelsus

...used in a product crucial to its future, while also buying out that drug’s royalty stream.Novo Nordisk A/S (CSE:NOVO...
...Stephen Hansen contributed to this report.TARGETSGLP-1R (GLP1R) - Glucagon-like peptide-1 receptor Paul Bonanos Rybelsus, oral semaglutide (NN9924, OG217SC) Novo Nordisk A/S Emisphere...
BioCentury | Sep 25, 2020
Product Development

Novo makes obesity pick as amylin/GLP-1 combo promises gastric bypass-like efficacy

...amylin/GLP-1 combo By stephen hansen, associate editor Novo Nordisk...
...for the even-greater efficacy the combo could produce. Novo Nordisk A/S...
...that mimics gastric bypass surgery.” Mads Thomsen, Novo Nordisk...
BioCentury | Sep 18, 2020
Finance

Lava’s $83M series C exemplifies evolution of Novo Ventures’ investing

...to allocate more capital to venture investments.Novo Holdings is the umbrella investment organization for the Novo Nordisk...
...focused on private and public venture investments. Novo Holdings is also the controlling shareholder of Novo Nordisk A/S...
BioCentury | Sep 2, 2020
Regulation

Sept. 1 Quick Takes: House committee to subpoena AbbVie on pricing; plus Athenex, Harmony, AZ, BMS, Novo, and cancer trial guidance

...candidate is under EMA review. Novo’s growth hormone deficiency drug gains FDA approvalFDA approved Sogroya somapacitan from Novo Nordisk A/S...
...Programmed cell death 1 ligand 1 Virginia Li AbbVie Inc. AstraZeneca plc the National Academy of Science FDA Bristol Myers Squibb Co. Novo Nordisk...
BioCentury | Aug 25, 2020
Finance

Seeing path for cholesterol-lowering program, Forbion launches start-up to house former Dezima molecule

...team includes two C-level executives with a history of entering deals around cardiovascular programs with Novo Nordisk A/S (CSE:NOVO...
BioCentury | Aug 21, 2020
Deals

Aug. 20 Quick Takes: Funding for Alzheon’s Alzheimer’s Phase III; plus Merck, FDA guidance, LumiraDx, RACE for Children, blood plasma and Novo-Evotec

...a request for comment from BioCentury.Evotec, Novo pair up to tackle kidney diseaseEvotec SE (Xetra:EVT) and Novo Nordisk A/S...
...E epsilon 4 Paul Bonanos ALZ-801, blu8499, NRM8499, NRM-8499 Keytruda, pembrolizumab (MK-3475, lambrolizumab) Alzheon Inc. Merck & Co. Inc. LumiraDx Ltd. NIH Evotec SE Novo Nordisk A/S covid-19 cov19dx cov19count cov19count...
BioCentury | Jul 28, 2020
Emerging Company Profile

Frazier, Marcadia founders reunite for rare endocrine diseases in MBX’s $34.6M A round

...$289.6 million) in cash and up to CHF86 million in milestones (see “Metabolic Wellspring” ). Novo Nordisk A/S...
BioCentury | Jul 10, 2020
Finance

How buysiders are sizing up commercial launches during the pandemic

...hit harder. She noted that the launch of the oral GLP-1 inhibitor Rybelsus semaglutide from Novo Nordisk A/S...
BioCentury | Jul 10, 2020
Finance

With an eye on ‘underserved’ Nordic biotechs, Eir raises €76M toward first fund

...fund, which Eir hopes will top out at about €100 million. Established biopharmas such as Novo Nordisk A/S...
...and endocrine disorders, stem cells, oncology and fibrosis. He added that diabetes, a key area Novo Nordisk...
BioCentury | Jul 10, 2020
Politics, Policy & Law

Pharmas to invest $1 billion in biotechs to fight AMR as bridge to market reforms

...billion dollar fund The ARM Fund has collected $1 billion from 23 pharmas and the Novo Nordisk...
...products will generate revenues. In a BioCentury Guest Commentary, Lars Rieben Sorenson, chairman of the Novo Nordisk...
Items per page:
1 - 10 of 1737